Discovery of Novel HPK1 Inhibitors via High‐Throughput Virtual Screening, Biological Evaluation, and Molecular Dynamics Simulation
Archiv der Pharmazie · 2026
DOI: 10.1002/ardp.70208 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2026. Verfasst von Xinglong Chi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Yongkang First People's Hospital and School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, China. Hauptthemen laut MEDLINE: Molecular Dynamics Simulation, Protein Serine-Threonine Kinases, Protein Kinase Inhibitors, High-Throughput Screening Assays. Die Arbeit nennt 41 Literaturangaben. Gefördert von: National Health and Family Planning Commission of the People's Republic of China, Zhejiang Medicine and Health Science and Technology Project, Scientific Research Fund of Zhejiang Provincial Education Department.
Abstract (Originalsprache)
Hematopoietic progenitor kinase 1 (HPK1) acts as a negative regulator of T‐cell receptor signaling, making it a high‐priority target for cancer immunotherapy. Addressing the scarcity of structurally novel HPK1 inhibitors, we constructed and validated a comprehensive high‐throughput virtual screening (HTVS) workflow to screen the ChemDiv database. This hierarchical protocol, characterized by a hybrid docking strategy and MM/GBSA rescoring, identified 10 candidates for biological testing. Experimental evaluation confirmed compound 8 as a potent hit, exhibiting an IC 50 of 1585 nM and 91.65% inhibition at 25 μM. Subsequent 500 ns molecular dynamics simulations validated the stability of the compound 8 –HPK1 complex ( ΔG binding = −41.59 kcal/mol), driven by critical interactions with residues GLU92 and CYS94. These findings establish compound 8 as a promising scaffold for structural optimization and demonstrate the robustness of our computational framework for HPK1 inhibitor discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Yongkang First People's Hospital and School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, China.
- Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, Zhejiang, China.
- School of Pharmacy, Hangzhou Medical College, Hangzhou, China.
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
- Institute of Bioinformatics and Medical Engineering, School of Electrical and Information Engineering, Jiangsu University of Technology, Changzhou, China.
ORCID-Profile: Wenhai Huang, Lei Xu, Xiangwei Xu, Siming Zhang
Förderung
- National Health and Family Planning Commission of the People's Republic of China
- Zhejiang Medicine and Health Science and Technology Project
- Scientific Research Fund of Zhejiang Provincial Education Department
Zitieren
APA
Chi, X., Chu, Y., Chen, R., Zhang, X., Xia, H., Pan, Y., Huang, W., Xu, L., Tang, Z., Xu, X., & Zhang, S. (2026). Discovery of Novel HPK1 Inhibitors via High‐Throughput Virtual Screening, Biological Evaluation, and Molecular Dynamics Simulation. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70208
Vancouver
Chi X, Chu Y, Chen R, Zhang X, Xia H, Pan Y, et al. Discovery of Novel HPK1 Inhibitors via High‐Throughput Virtual Screening, Biological Evaluation, and Molecular Dynamics Simulation. Archiv der Pharmazie. 2026. doi:10.1002/ardp.70208
BibTeX
@article{Chi2026,
author = {Chi, Xinglong and Chu, Yiqun and Chen, Roufen and Zhang, Xin and Xia, Heye and Pan, Youlu and Huang, Wenhai and Xu, Lei and Tang, Zhan and Xu, Xiangwei and Zhang, Siming},
title = {Discovery of Novel HPK1 Inhibitors via High‐Throughput Virtual Screening, Biological Evaluation, and Molecular Dynamics Simulation},
journal = {Archiv der Pharmazie},
year = {2026},
doi = {10.1002/ardp.70208}
}
EUVIMED